ADCT has 36-month beta value of 1.67. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADCT is 55.62M, and currently, short sellers hold a 1.60% ratio of that float. The average trading volume of ADCT on April 26, 2024 was 738.10K shares.
ADCT) stock’s latest price update
Adc Therapeutics SA (NYSE: ADCT)’s stock price has dropped by -7.11 in relation to previous closing price of 4.78. Nevertheless, the company has seen a loss of -6.72% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-13 that ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADCT’s Market Performance
ADCT’s stock has fallen by -6.72% in the past week, with a monthly rise of 2.07% and a quarterly rise of 71.43%. The volatility ratio for the week is 6.25% while the volatility levels for the last 30 days are 8.75% for Adc Therapeutics SA The simple moving average for the past 20 days is -4.42% for ADCT’s stock, with a 101.76% simple moving average for the past 200 days.
Analysts’ Opinion of ADCT
Many brokerage firms have already submitted their reports for ADCT stocks, with Guggenheim repeating the rating for ADCT by listing it as a “Buy.” The predicted price for ADCT in the upcoming period, according to Guggenheim is $11 based on the research report published on March 28, 2024 of the current year 2024.
BofA Securities gave a rating of “Underperform” to ADCT, setting the target price at $2 in the report published on April 24th of the previous year.
ADCT Trading at -4.22% from the 50-Day Moving Average
After a stumble in the market that brought ADCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.49% of loss for the given period.
Volatility was left at 8.75%, however, over the last 30 days, the volatility rate increased by 6.25%, as shares surge +5.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.21% upper at present.
During the last 5 trading sessions, ADCT fell by -6.72%, which changed the moving average for the period of 200-days by +140.00% in comparison to the 20-day moving average, which settled at $4.66. In addition, Adc Therapeutics SA saw 167.47% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ADCT
Current profitability levels for the company are sitting at:
- -2.43 for the present operating margin
- 0.95 for the gross margin
The net margin for Adc Therapeutics SA stands at -3.44. The total capital return value is set at -0.59. Equity return is now at value -705.53, with -54.16 for asset returns.
Based on Adc Therapeutics SA (ADCT), the company’s capital structure generated -3.35 points at debt to capital in total, while cash flow to debt ratio is standing at -1.04. The debt to equity ratio resting at -0.77. The interest coverage ratio of the stock is -3.24.
Currently, EBITDA for the company is -145.78 million with net debt to EBITDA at 1.06. When we switch over and look at the enterprise to sales, we see a ratio of 3.07. The receivables turnover for the company is 2.76for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.97.
Conclusion
To put it simply, Adc Therapeutics SA (ADCT) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
